A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) (NCT06455202)

🧪 Interventions in This Study

• barzolvolimab (BIOLOGICAL)
• Matching placebo (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (245 Sites)

Showing the first 25 of 245 sites.

• Allervie Clinical Research - Cullman — Cullman, Alabama
• Research Solutions of Arizona PC — Litchfield Park, Arizona
• Medical Research of Arizona a division of Allergy, Asthma, & Immunology, Assoc. Ltd. — Scottsdale, Arizona
• Center for Dermatology & Plastic Surgery — Scottsdale, Arizona
• Kern Research, Inc. — Bakersfield, California
• UCLA Clinical Trials Contracts & Strategic Relations — Los Angeles, California
• California Allergy and Asthma Medical Group — Los Angeles, California
• LA Universal Research Center, Inc. — Los Angeles, California
• Allergy and Asthma Associates of Southern Cal — Mission Viejo, California
• Huntington Asthma & Allergy Center — Pasadena, California
• Apex Clinical Research — San Diego, California
• WR-MCCR — San Diego, California
• University Clinical Trials — San Diego, California
• Clinical Science Institute — Santa Monica, California
• Raffi Tachdjian MD, Inc — Santa Monica, California
• Clarity Dermatology, PLLC — Castle Rock, Colorado
• Asthma and Allergy Associates — Colorado Springs, Colorado
• Driven Research LLC — Coral Gables, Florida
• Palm Beach Dermatology Group — Delray Beach, Florida
• Dolphin Medical Research — Doral, Florida
• South FL Clinical Research LLC — Miami, Florida
• Dade Florida Clinical Research Center — Miami, Florida
• Deluxe Health Center — Miami Lakes, Florida
• Revival Clinical Research — Orlando, Florida
• International Clinical Research - FL LLC — Sanford, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Spontaneous Urticaria

• Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. — CABA, Buenos Aires
• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up — Bakersfield, California
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Birmingham, Alabama
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Birmingham, Alabama
• Remibrutinib in Real-world Clinical Practice — Kirksville, Missouri

Explore by condition: All Chronic Spontaneous Urticaria clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.